2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on ES-SCLC: Does the Addition of Tremelimumab to Durvalumab + Chemo Provide Additional Benefit?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Ryan Gentzler
By 2020 ASCO Virtual Direct™ Highlights FEATURING Ryan Gentzler
0 views
August 4, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
Lung
08:15
2020 ASCO Virtual Direct™ Highlights

2020 Update on Radiation Therapy in Lung Cancer: Is High-Dose Twice-…

Feat. H. Borghaei
10:59
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in NSCLC: Is Adjuvant Osimertin…

Feat. H. Borghaei
06:00
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in mNSCLC: Is Trastuzumab Derux…

Feat. R. Gentzler
03:50
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lung Cancer Management During COVID-19: What Is …

Feat. R. Gentzler
12:36
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in mNSCLC: Should We Still Consider Chemother…

Feat. R. Gentzler
08:41
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on ES-SCLC: Does the Addition of Tremelimumab to Du…

Feat. R. Gentzler